{"id":52557,"date":"2023-01-05T07:02:22","date_gmt":"2023-01-05T06:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/"},"modified":"2023-01-05T07:02:22","modified_gmt":"2023-01-05T06:02:22","slug":"innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/","title":{"rendered":"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI"},"content":{"rendered":"
\n

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company will present the latest clinical data of FGFR inhibitor gunagratinib (ICP-192) for the treatment of cholangiocarcinoma at the 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on January 19-21, 2023, which will be held online and offline in San Francisco, U.S.\n<\/p>\n

\nThe 2023 ASCO GI Cancers Symposium is an influential academic exchange event in the gastrointestinal cancer in the world, offering the latest innovative science, solution-focused strategies, and multidisciplinary approaches in GI cancer treatment, research, and care.\n<\/p>\n

\nPoster Presentation<\/b>\n<\/p>\n

\nTitle: Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study\n<\/p>\n

\nAbstract Number: 572
\n
Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract<\/a>
Presentation Time: 12:00 PM -1:30 PM, Jan. 20, U.S. Time
\n
Presenter: Professor Ye Guo\n<\/p>\n

\nAbout InnoCare<\/b>\n<\/p>\n

\nInnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and\/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Chunhua Lu
\n
86-10-66609879
\n
chunhua.lu@innocarepharma.com<\/a>\n<\/p>\n

\nInvestor Relations<\/b>
86-10-66609999
\n
ir@innocarepharma.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company will present the latest clinical data of FGFR inhibitor gunagratinib (ICP-192) for the treatment of cholangiocarcinoma at the 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52557","6":"format-standard","7":"category-industry"},"yoast_head":"\nInnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company will present the latest clinical data of FGFR inhibitor gunagratinib (ICP-192) for the treatment of cholangiocarcinoma at the 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-05T06:02:22+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI\",\"datePublished\":\"2023-01-05T06:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\\\/\"},\"wordCount\":251,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\\\/\",\"name\":\"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-01-05T06:02:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/","og_locale":"en_US","og_type":"article","og_title":"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI - Pharma Trend","og_description":"BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company will present the latest clinical data of FGFR inhibitor gunagratinib (ICP-192) for the treatment of cholangiocarcinoma at the 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-05T06:02:22+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI","datePublished":"2023-01-05T06:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/"},"wordCount":251,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/","url":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/","name":"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-01-05T06:02:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innocare-to-present-latest-clinical-data-of-gunagratinib-at-the-upcoming-2023-asco-gi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52557"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52557\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}